Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993646 | 1.00 | GAA (0.36) | GAASCN9AEPHX2NR1H2NR1H3 | |
| SCHEMBL4995158 | 0.86 | EPHX2 (0.41) | GAASCN9AEPHX2 | |
| SCHEMBL4249390 | 0.86 | EPHX2 (0.41) | GAASCN9AEPHX2 | |
| SCHEMBL4250978 | 0.81 | SCN9A (0.43) | SCN9A | |
| SCHEMBL4249470 | 0.81 | SCN9A (0.43) | SCN9A | |
| SCHEMBL14093684 | 0.81 | PSEN1 (0.35) | — | |
| SCHEMBL8201291 | 0.81 | PSEN1 (0.35) | — | |
| SCHEMBL8207401 | 0.79 | HTR2C (0.36) | NR1H2NR1H3HTR2C | |
| SCHEMBL4995341 | 0.79 | HTR2C (0.36) | NR1H2NR1H3HTR2C | |
| Hydrochloric Acid SCHEMBL4995346 | 0.78 | HTR2C (0.36) | NR1H2NR1H3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414049-B2 | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414049-B2 | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414049-B2 | 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103133-A1 | 4-OXO-2,3,4,5-TETRAHYDRO-BENZO[b][1,4]DIAZEPINE DERIVATIVES | BACE1, BACE2, PSEN1 | GAA 271/4885SCN9A 1371/4885EPHX2 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.